Opinion on Pharmaceutical Contract Research Organizations in North America

Published within

« | 1 | 2 | 3 | 4 | » »|

Type Product title / description Pub Price
CommentWire
CommentWire

Abbott: meta-analysis is good news for psoriasis drug but approval remains a hurdle

A new article in the Journal of the American Medical Association reveals that interleukin-12/23 inhibitors such as Abbott's Ozespa do not raise cardiovascular risks in psoriasis patients compared to placebo or TNF inhibitors. Abbott will welcome the news, but Datamonitor believes that while Ozespa is a key contender if resubmitted for approval, hurdles remain as more extensive data are needed.

Published By Datamonitor
24 Aug 2011
CommentWire
CommentWire

Allergan: new data suggest Botox treats chronic migraine

Top-line Phase III clinical trial data of Botox for the prophylactic treatment of chronic migraine showed a statistically significant decrease in the number of headache days at 24 weeks. Depending on full data results expected in mid-2009, Botox could become the first approved treatment for this debilitating and largely underserved condition.

Published By Datamonitor
12 Sep 2008
CommentWire
CommentWire

Amarin: RNA therapy results announced to attract suitors

In an effort to generate interest from potential partners in its investigational myasthenia gravis agent, EN101, Amarin has announced positive final efficacy data from an exploratory Phase IIa study. Although these promising data support a symptomatic effect, greater value could be expected if immunosuppressant activity is also demonstrated in later trials.

Published By Datamonitor
11 Jun 2009
Expert View
Expert View

APA meeting 2009: clinical data support potential label expansions in GAD

In May 2009, Datamonitor attended the annual American Psychiatric Association meeting in San Francisco. At the conference, AstraZeneca and Pfizer presented data for two high-profile products for which they hope to gain label expansions into generalized anxiety disorder. However, both companies have found pursuing this expansion to be challenging.

Published By Datamonitor
29 May 2009
Expert View
Expert View

APA meeting 2009: new schizophrenia products and depot formulations

The annual meeting of the American Psychiatric Association is the year's largest psychiatry event. This year's conference in San Francisco indicated that long-acting depot versions of atypical antipsychotics continue to prove useful tools in the treatment of schizophrenia. In addition, new potential market entrants reported mixed data from new oral antipsychotics.

Published By Datamonitor
29 May 2009
Expert View
Expert View

APA meeting 2009: novel drugs face challenges in mature depression and bipolar markets

At the recent meeting of the American Psychiatric Association, Forest/Gedeon Richter and Lundbeck attracted attention following the presentation of positive data for two novel drugs in bipolar disorder and depression, respectively. Given that both these indications are highly competitive and genericized markets, the companies are already seeking to differentiate their respective products.

Published By Datamonitor
29 May 2009
Expert View
Expert View

APA meeting 2009: Shire to maintain market leading status in ADHD

At the American Psychiatric Association's annual meeting, British pharmaceutical firm Shire presented data on its diverse attention deficit hyperactivity disorder portfolio, covering three key products. Through continued astute portfolio management, Datamonitor forecasts Shire to remain the market leader with a 40% share of the ADHD sector by 2017.

Published By Datamonitor
29 May 2009
Expert View
Expert View

ASH 2009: competition between Velcade and Revlimid intensifies in multiple myeloma

Datamonitor attended this year's American Society of Hematology annual meeting in New Orleans, focusing on key developments in hematological malignancies. While recent trial results are likely to support new applications for Velcade and Revlimid in first-line multiple myeloma, the data also suggest that the future of treatment may actually be a combination of the two.

Published By Datamonitor
11 Dec 2009
Expert View
Expert View

ASH 2009: Novartis looks to position Tasigna as an alternative to Gleevec in CML

At this year's American Society of Hematology meeting, researchers presented results from a Phase III study comparing Tasigna and Gleevec in newly diagnosed chronic myeloid leukemia. While Tasigna's efficacy is impressive, it is unlikely that the drug will achieve the same market penetration as Gleevec in newly diagnosed patients due to fierce competition from Sprycel.

Published By Datamonitor
11 Dec 2009
CommentWire
CommentWire

AstraZeneca: Zactima development continues apace in lung cancer

The continuing development of Zactima in non-small-cell lung cancer will be welcome news for AstraZeneca, following the recent failure of Recentin in the same indication. Success in this indication now hinges on whether Zactima's mechanism of action can translate into notable clinical benefit.

Published By Datamonitor
14 Mar 2008

« | 1 | 2 | 3 | 4 | » »|

No help is available.